Efficacy

Keytruda (Pembrolizumab) Efficacy in Lymphoma

Keytruda, also known by its generic name pembrolizumab, is an immune checkpoint inhibitor that has shown efficacy in the treatment of various types of cancer, including lymphoma. Specifically, it has been studied in the treatment of Hodgkin lymphoma (HL) and primary mediastinal large B-cell lymphoma (PMBCL), a subtype of non-Hodgkin lymphoma. In Hodgkin lymphoma, pembrolizumab has been used after failure of autologous stem cell transplant (ASCT) or after at least two prior therapies when ASCT is not an option. Clinical trials have demonstrated that pembrolizumab can induce a significant response rate in patients with relapsed or refractory HL, offering a valuable therapeutic option for those with limited treatment choices.

For patients with PMBCL who are not candidates for ASCT, pembrolizumab has been granted accelerated approval based on overall response rates observed in clinical studies. While the long-term benefits are still under investigation, the early data suggest that pembrolizumab can provide a meaningful clinical response in this hard-to-treat population. It is important to note that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Monjuvi (Tafasitamab-cxix) Efficacy in Lymphoma

Monjuvi, with the generic name tafasitamab-cxix, is a CD19-directed cytolytic antibody indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This medication is not intended for patients who are eligible for autologous stem cell transplant. Tafasitamab-cxix, when used in combination with lenalidomide, has shown to improve overall response rates and progression-free survival in this patient population.

The approval of Monjuvi in combination with lenalidomide was based on a multicenter, single-arm trial that demonstrated a significant efficacy in patients with relapsed or refractory DLBCL. The combination therapy not only improved response rates but also had a manageable safety profile, making it a promising therapeutic option for patients who have limited treatment choices due to the aggressive nature of relapsed or refractory DLBCL. As with other accelerated approvals, confirmatory trials are required to verify and describe the clinical benefits of tafasitamab-cxix.